By Heritage Cannabis Holdings Corp. on Wednesday, 03 February 2021
Category: Vertically Integrated

Heritage Cannabis Purefarma and Pura Vida products now available on genetics site myDNA.live

EndoDNA website myDNA.live identifies how an individual’s specific genetic makeup interacts with cannabinoids and terpenes

Its partly-owned subsidiary launched the EndoDNA test in late 2019, which analyzes over 500 genes and more than 550,000 Single Nucleotide Polymorphisms in the human body

Heritage Cannabis Holdings Corp () () (FRA:2UE) reported that the company’s Purefarma and Pura Vida products are now available on the EndoDNA website myDNA.live, which identifies how an individual’s specific genetic makeup interacts with cannabinoids and terpenes. 

Heritage Cannabis said the EndoDNA test, which is available on endodna.com, guides individuals based on these results, and provides genetically aligned product recommendations, which will offer individuals a more optimal experience with cannabis.

“Having our products available through myDNA.live is another channel for consumers to access our award-winning products, and to provide individuals with the tools and resources to make confident decisions when incorporating cannabis into their lives,” Heritage Cannabis CEO Clint Sharples said in a statement. 

READ: Heritage Cannabis receives first order from the Ontario Cannabis Store for its Purefarma and Pura Vida products

He added: “We continue to expand our product offerings throughout Canada’s provincial boards, and online platforms in an effort to maximize consumer access to our sought-after products.”

Endocanna Health CEO Len May also weighed in on the announcement, stating: “EndoDNA is truly a personalized experience when it comes to selecting cannabis products with the right cannabinoid profile and assists with choosing formulation, dosage, and best delivery method for consumers’ needs.”

He continued: “Finding the right product for specific needs can be challenging and now with Purefarma and Pura Vida added to the products offered on myDNA.live, consumers will have access to a greater selection of high-quality products.”

Heritage Cannabis noted that Endocanna Health Inc, its partly-owned subsidiary, launched the EndoDNA test in late 2019, which analyzes over 500 genes and more than 550,000 Single Nucleotide Polymorphisms in the human body, and provides a personalized Endo·Decoded report through a secure portal.

Heritage Cannabis is a vertically-integrated cannabis provider that currently has two Health Canada-approved licensed producers, through its subsidiaries Voyage Cannabis Corp and CannaCure Corp, both of which are regulated under the Cannabis Act Regulations. 

The company recently acquired Canadian recreational and medical cannabis company Premium 5 Ltd, which Heritage Cannabis expects will make it a leader in the extract and extract derivatives market, as Premium 5 is a premium provider of Cannabis 2.0 hydrocarbon and solventless concentrates in Canada. 

Contact Sean at sean@proactiveinvestors.com

Related Posts